Announcement Ionis intends to form a supplemental page to further submit its potential by the end of the year to extend Tryngolza into an extreme hypertriglyceridemia. If accepted, then William Blair will strengthen its hope, claiming the antisense drug to be known as a transformational one for th...
Announcement Innate Pharma SA proudly declared that they have received clearance by the US Food and Drug Administration (FDA) for the confirmatory Phase 3 protocol for lacutamab in cutaneous T-cell lymphomas (CTCL), undoubtedly with the green signal to proceed with the trial. The TELLOMAK 3 ...
Announcement The new generation of companies has been keeping an eye on the niche-sized hair loss market with fingers crossed for the best new scientific focus and formulations to discover treatments not only effective and safe, but also excelling commercially. The progress of the GLP-1 weight los...
Announcement Hinge Health (HNGE), a leading digital health company offering personalised programs to help individuals deal with musculoskeletal (MSK) pain via virtual care, lifestyle support and exercise therapy, has witnessed a rise in share. The company merges an AI-sponsored platform with human...
Announcement Eli Lilly has agreed with the legal body, the US government and has entered an agreement to extend its reach to its obesity treatments for self-pay patients and Medicare beneficiaries. This will prominently mitigate the monthly out-of-the-budget costs. The efforts behind this decision ...
Announcement The major IAVI’s Lassa virus (LASV) vaccine candidate findings from a first-in-human, Phase 1 clinical trial are now on the page of New England Journal of Medicine. The published data elaborates that one dose of the vaccine provokes comprehensive long-standing immune responses a...
Announcement GeneDx, a captain of improved health outcomes, shores delivering excellence via genomic insights, has hinted that it will soon reveal the research findings at a time of four major sessions at the National Society of Genetic Counsellors (NSGC) Annual Meeting 2025. The PhD, FACMG, SVP of...
Announcement Eli Lilly’s amylin agonist, eloralintide, successfully showed 20% of weight loss in its mid-stage study that marked the course for the phase 3 trial. The analyst, William Blair, claimed that eloralintide examines the amylin agonist class. The Phase 2 trial for the same involved ...
Announcement Novo Nordisk and Eli Lilly will provide their GLP-1 drugs via President Donald Trump’s direct-to-consumer marketplace for worth $350 per month. The future pills manufactured by industries like Novo’s oral Wegovy or any GLP-1 pill that received approval later will be availa...
Announcement IDT Biologika GmbH, the leading European auxiliary of SK Bioscience, has sailed on a full-scale ocean to extend its contract development and manufacturing (CDMO) business in biopharmaceuticals and vaccines. Last month and the start of November, the IDT took part in three of the compan...
